# A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M

> **NCT07183371** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Oxford** · enrollment: 360 (estimated)

## Conditions studied

- Malaria,Falciparum

## Interventions

- **BIOLOGICAL:** R21
- **BIOLOGICAL:** RH5.1
- **BIOLOGICAL:** R78C
- **BIOLOGICAL:** Matrix-M™
- **BIOLOGICAL:** Rabivax-S
- **BIOLOGICAL:** Menveo
- **BIOLOGICAL:** Avaxim 80

## Key facts

- **NCT ID:** NCT07183371
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-12-15
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2026-03-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07183371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07183371, "A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07183371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*